Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis.
Cochleates containing amphotericin B (CAMB) were administered orally at doses ranging from 0 to 40 mg/kg of body weight/day for 14 days in a murine model of systemic aspergillosis. The administration of oral doses of CAMB (20 and 40 mg/kg/day) resulted in a survival rate of 70% and a reduction in colony counts of more than 2 logs in lungs, livers, and kidneys. Orally administered CAMB shows promise for the treatment of aspergillosis.
Delmas
G
G
Public Health Research Institute, 225 Warren Street, Newark, NJ 07103, USA.
Park
S
S
Chen
Z W
ZW
Tan
F
F
Kashiwazaki
R
R
Zarif
L
L
Perlin
D S
DS
D000666:Amphotericin B / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D003840:Deoxycholic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D007668:Kidney / Q000378:metabolism / Q000382:microbiology; D008099:Liver / Q000378:metabolism / Q000382:microbiology; D008168:Lung / Q000378:metabolism / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D014677:Pharmaceutical Vehicles; D016019:Survival Analysis; D014018:Tissue Distribution
D000935:Antifungal Agents; D004338:Drug Combinations; D014677:Pharmaceutical Vehicles; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination